Serina Therapeutics Inc (SER) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.
Contact details
Important dates
General stock information
- Short code:
- SER
- ISIN:
- US81751A1088
- Market cap:
- $46.51 million
- Shares in issue:
- 8.89 million
- Sector:
- Biotechnology
- Exchange:
- -
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.